Equities Analysts Issue Forecasts for Pro-Dex Q1 Earnings

Pro-Dex, Inc. (NASDAQ:PDEX) – Equities research analysts at Ascendiant Capital Markets boosted their Q1 2027 earnings per share (EPS) estimates for shares of Pro-Dex in a research report issued on Thursday, September 10th. Ascendiant Capital Markets analyst E. Woo now forecasts that the medical instruments supplier will post earnings per share of $0.67 for the quarter, up from their prior estimate of $0.66. Ascendiant Capital Markets has a “Buy” rating and a $74.00 price target on the stock. The consensus estimate for Pro-Dex’s current full-year earnings is $2.78 per share. Ascendiant Capital Markets also issued estimates for Pro-Dex’s Q2 2027 earnings at $0.72 EPS, Q3 2027 earnings at $0.82 EPS, FY2027 earnings at $3.09 EPS, Q1 2028 earnings at $0.77 EPS, Q2 2028 earnings at $0.81 EPS, Q3 2028 earnings at $0.86 EPS, Q4 2028 earnings at $0.91 EPS and FY2028 earnings at $3.36 EPS.

Pro-Dex (NASDAQ:PDEX) last released its quarterly earnings results on Thursday, September 3rd. The medical instruments supplier reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.20. Pro-Dex had a return on equity of 25.13% and a net margin of 17.62%.The firm had revenue of $20.40 million during the quarter, compared to the consensus estimate of $19.20 million.

Other equities research analysts also recently issued research reports about the company. Weiss Ratings raised Pro-Dex from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, September 4th. Zacks Research raised Pro-Dex to a “hold” rating in a research report on Tuesday, May 19th. Finally, Wall Street Zen upgraded shares of Pro-Dex from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $74.00.

Pro-Dex Trading Up 0.5%

Pro-Dex stock opened at $66.91 on Wednesday. The firm has a 50-day moving average of $62.68 and a 200-day moving average of $58.18. Pro-Dex has a one year low of $23.47 and a one year high of $77.00. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.10 and a quick ratio of 2.45. The company has a market cap of $214.31 million, a price-to-earnings ratio of 16.20 and a beta of 0.06.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Navellier & Associates Inc. acquired a new stake in shares of Pro-Dex during the 2nd quarter valued at $322,000. Bank of New York Mellon Corp bought a new position in shares of Pro-Dex during the second quarter worth about $678,000. Corsair Capital Management L.P. acquired a new position in shares of Pro-Dex in the 1st quarter worth approximately $532,000. Punch & Associates Investment Management Inc. lifted its holdings in Pro-Dex by 2.9% in the first quarter. Punch & Associates Investment Management Inc. now owns 61,735 shares of the medical instruments supplier’s stock valued at $3,032,000 after buying an additional 1,735 shares during the period. Finally, Morgan Dempsey Capital Management LLC lifted its stake in shares of Pro-Dex by 6.2% in the 1st quarter. Morgan Dempsey Capital Management LLC now owns 5,808 shares of the medical instruments supplier’s stock valued at $286,000 after purchasing an additional 339 shares during the period. 15.28% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Kirk Richard Lee Van, Jr. sold 765 shares of the firm’s stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $59.36, for a total value of $45,410.40. Following the sale, the chief executive officer directly owned 79,228 shares in the company, valued at approximately $4,702,974.08. This trade represents a 0.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Alisha Charlton sold 2,300 shares of the company’s stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $61.30, for a total transaction of $140,990.00. Following the transaction, the chief financial officer owned 21,870 shares of the company’s stock, valued at approximately $1,340,631. This represents a 9.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 22,300 shares of company stock worth $1,351,657. 45.90% of the stock is currently owned by corporate insiders.

Key Pro-Dex News

Here are the key news stories impacting Pro-Dex this week:

• Positive Sentiment: Ascendiant raises long-term earnings forecasts: Ascendiant Capital Markets lifted its FY2027 EPS estimate to $3.09 from $2.78 and maintained a “Buy” rating with a $74 price target. The firm projects EPS of $3.36 for FY2028, with quarterly estimates ranging from $0.77 to $0.91. The higher forecasts suggest expectations for continued profit growth at the medical-instruments supplier. Ascendiant Capital Markets analyst coverage
• Positive Sentiment: Several near-term estimates were increased: Ascendiant raised its Q1 2027 EPS forecast to $0.67 from $0.66, Q2 2027 to $0.72 from $0.69, and Q3 2027 to $0.82 from $0.74. These upward revisions provide a potential catalyst for the stock by indicating improving expectations for upcoming results.
• Positive Sentiment: Recent results exceeded expectations: Pro-Dex’s latest quarterly report showed $0.87 in EPS versus the $0.67 consensus estimate and revenue of $20.40 million versus estimates of $19.20 million. The company also reported a 17.62% net margin and 25.13% return on equity, reinforcing the bullish earnings narrative.
• Positive Sentiment: Institutional interest increased: Several funds initiated or expanded positions, including Bank of New York Mellon, Corsair Capital Management, Navellier & Associates, and California State Teachers’ Retirement System. Institutional investors collectively own approximately 15.28% of PDEX shares.
• Negative Sentiment: CEO disclosed a stock sale: CEO Kirk Richard Lee Van, Jr. sold 765 shares for approximately $45,410 under a pre-arranged Rule 10b5-1 trading plan. The sale reduced his holdings by less than 1%, limiting its significance, but insider selling can be a modest sentiment headwind. Pro-Dex CEO stock sale

Pro-Dex Company Profile

Pro-Dex, Inc is a medical device manufacturer that designs, develops and produces powered surgical instruments and related equipment. The company primarily serves original equipment manufacturers (OEMs), which incorporate Pro-Dex products into surgical systems sold under their own brands.

Its product portfolio includes battery-powered and electric handpieces, controllers, drivers, saws, microdebriders and other precision instruments used in medical and dental procedures. Pro-Dex also provides related components and accessories, including batteries, chargers and instrument controls, as well as engineering, manufacturing and product-development support for its customers.

Based in Irvine, California, Pro-Dex serves customers in the United States and international markets.